Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : Apls save search
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
Published: 2023-10-17 (Crawled : 11:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -1.4%
H: 2.43%
C: 0.02%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -2.01%
H: 2.36%
C: 1.96%
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 0.66%
H: 1.2%
C: -3.55%
kidney positive week results
Aspaveli® (pegcetacoplan) receives positive CHMP opinion for treatment of PNH
Published: 2021-10-15 (Crawled : 12:00) - prnewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: -2.48%
treatment positive chmp
Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH
Published: 2021-10-15 (Crawled : 12:00) - globenewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: -2.48%
treatment positive chmp
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 2.31%
H: 3.23%
C: 0.02%
treatment positive results phase 3 topline
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 2.31%
H: 3.23%
C: 0.02%
treatment positive results phase 3 topline
Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
Published: 2021-03-10 (Crawled : 14:24) - globenewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 2.07%
H: 4.18%
C: 3.86%
phase 2 positive
Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH
Published: 2020-12-10 (Crawled : 11:01) - globenewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: 0.1%
H: 3.46%
C: 0.25%
positive results phase 3 topline
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.